Efficacy of newly initiating interferon β-1a (scIFNβ1a) vs oral disease-modifying drugs in patient with multiple sclerosis.

Trial Profile

Efficacy of newly initiating interferon β-1a (scIFNβ1a) vs oral disease-modifying drugs in patient with multiple sclerosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
    • 22 Nov 2017 New trial record
    • 28 Oct 2017 Results assessing efficacy of newly initiating subcutaneous interferon beta-1a vs oral disease-modifying drugs (DMDs) in patient with multiple sclerosis, were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top